Please try another search
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Nello Mainolfi | 43 | 2017 | Co-Founder, President, CEO & Director |
Elena H. Ridloff | 42 | 2021 | Independent Director |
Jeffrey W. Albers | 51 | 2020 | Independent Director |
Gorjan Hrustanovic | 35 | 2020 | Independent Director |
Joanna Caroline Horobin | 69 | 2018 | Independent Director |
John M. Maraganore | 62 | 2022 | Independent Director |
Pamela Esposito | 49 | 2020 | Independent Director |
Felix James Baker | 55 | 2024 | Lead Independent Director |
Bruce L. Booth | 50 | 2015 | Co-Founder & Independent Chairman |
Leigh Morgan | 55 | 2022 | Independent Indepednet Director |
Victor Sandor | 58 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review